Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous bone marrow-derived mesenchymal stem cells (Tehran University of Medical Sciences)
- Development stage
- Unknown
- Lead developer
- Tehran University of Medical Sciences
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Ophthalmic, Intravitreal
01
Overview
This investigational autologous cell therapy consists of mesenchymal stem cells (MSCs) derived from the patient's own bone marrow. Developed by the Tehran University of Medical Sciences, it was evaluated in a Phase 1 pilot study (NCT00550498) for the treatment of refractory ocular manifestations of Behcet's disease, specifically retinal vasculitis. The therapy involves harvesting bone marrow, expanding the mononuclear cells ex vivo through repeated passages, and administering the final cell product via intravitreal injection. The therapeutic rationale is based on the immunomodulatory and tissue-repair properties of MSCs, which are intended to modulate the inflammatory immune response and promote repair of ocular lesions in patients who have failed conventional immunosuppressive treatments.
- Other names
- Autologous Stem Cell Transplantationautologous mesenchymal stem cellsBM-MSCs
Beyond the preview
Go deeper on autologous bone marrow-derived mesenchymal stem cells (Tehran University of Medical Sciences).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous bone marrow-derived mesenchymal stem cells (Tehran University of Medical Sciences).